BACKGROUND & AIMS: Sleep disturbances are common in patients with cirrhosis, but their determinants and effects on health-related quality of life are not well-understood. We investigated the prevalence of disturbed sleep in these patients, factors associated with sleep disruption, and effects on quality of life. METHODS: We performed a prospective, cross-sectional study of 193 stable ambulatory patients with cirrhosis (154 with decompensated cirrhosis). Participants completed the Pittsburgh Sleep Quality Index (to assess sleep quality), the Chronic Liver Disease Questionnaire (CLDQ), and muscle cramp questionnaires and underwent neurocognitive testing. Actigraphy was performed in a subset of patients with normal and disturbed sleep. We collected serum samples from subjects with normal and disturbed sleep and performed non-targeted metabolomic analyses. RESULTS: Of the study subjects, 157 (81%) had disturbed sleep, with Pittsburgh Sleep Quality Index scores >5. Disturbed sleep was associated with muscle cramps, daytime somnolence, and decreased quality of life on the basis of CLDQ scores. Factors independently associated with disturbed sleep in logistic regression analysis included hypoalbuminemia, opiate therapy, and muscle cramps. Disturbed sleep was independently associated with CLDQ score (correlation parameter, -36.6; 95% confidence interval, -24 to -49; P < .001) on linear regression. Disturbed sleep was associated with neurocognitive impairment and with significantly delayed bedtime and decreased total sleep time, measured by actigraphy. Disturbed sleep was associated with metabolome signatures of alterations to the intestinal microbiome and lipid, arginine, and urea cycle metabolism. CONCLUSIONS: Most patients with advanced cirrhosis (81%) have disturbed sleep. This has negative effects on quality of life and is associated with disruptions of several metabolic pathways, including metabolism by the intestinal microbiota.
BACKGROUND & AIMS:Sleep disturbances are common in patients with cirrhosis, but their determinants and effects on health-related quality of life are not well-understood. We investigated the prevalence of disturbed sleep in these patients, factors associated with sleep disruption, and effects on quality of life. METHODS: We performed a prospective, cross-sectional study of 193 stable ambulatory patients with cirrhosis (154 with decompensated cirrhosis). Participants completed the Pittsburgh Sleep Quality Index (to assess sleep quality), the Chronic Liver Disease Questionnaire (CLDQ), and muscle cramp questionnaires and underwent neurocognitive testing. Actigraphy was performed in a subset of patients with normal and disturbed sleep. We collected serum samples from subjects with normal and disturbed sleep and performed non-targeted metabolomic analyses. RESULTS: Of the study subjects, 157 (81%) had disturbed sleep, with Pittsburgh Sleep Quality Index scores >5. Disturbed sleep was associated with muscle cramps, daytime somnolence, and decreased quality of life on the basis of CLDQ scores. Factors independently associated with disturbed sleep in logistic regression analysis included hypoalbuminemia, opiate therapy, and muscle cramps. Disturbed sleep was independently associated with CLDQ score (correlation parameter, -36.6; 95% confidence interval, -24 to -49; P < .001) on linear regression. Disturbed sleep was associated with neurocognitive impairment and with significantly delayed bedtime and decreased total sleep time, measured by actigraphy. Disturbed sleep was associated with metabolome signatures of alterations to the intestinal microbiome and lipid, arginine, and urea cycle metabolism. CONCLUSIONS: Most patients with advanced cirrhosis (81%) have disturbed sleep. This has negative effects on quality of life and is associated with disruptions of several metabolic pathways, including metabolism by the intestinal microbiota.
Authors: Sara Montagnese; Benita Middleton; Ali R Mani; Debra J Skene; Marsha Y Morgan Journal: Am J Gastroenterol Date: 2010-03-23 Impact factor: 10.864
Authors: G Marchesini; G Bianchi; P Amodio; F Salerno; M Merli; C Panella; C Loguercio; G Apolone; M Niero; R Abbiati Journal: Gastroenterology Date: 2001-01 Impact factor: 22.682
Authors: M Llansola; J L Cantero; E Hita-Yañez; M J Mirones-Maldonado; B Piedrafita; H Ahabrach; M Errami; A Agusti; V Felipo Journal: Neuroscience Date: 2011-11-12 Impact factor: 3.590
Authors: Isabelle Hourmand-Ollivier; Marie-Astrid Piquet; Jean Pierre Toudic; Pierre Denise; Thông Dao Journal: World J Gastroenterol Date: 2006-04-14 Impact factor: 5.742
Authors: Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet Journal: PLoS One Date: 2013-04-02 Impact factor: 3.240
Authors: Elliot B Tapper; Neehar D Parikh; Akbar K Waljee; Michael Volk; Noelle E Carlozzi; Anna S-F Lok Journal: Am J Gastroenterol Date: 2018-03-13 Impact factor: 10.864
Authors: Sophie L Allen; Jonathan I Quinlan; Amritpal Dhaliwal; Matthew J Armstrong; Ahmed M Elsharkawy; Carolyn A Greig; Janet M Lord; Gareth G Lavery; Leigh Breen Journal: Am J Physiol Gastrointest Liver Physiol Date: 2020-11-25 Impact factor: 4.052
Authors: John H Holden; Hani Shamseddeen; Amy W Johnson; Benjamin Byriel; Kavitha Subramoney; Yao-Wen Cheng; Akira Saito; Marwan Ghabril; Naga Chalasani; Greg A Sachs; Eric S Orman Journal: J Palliat Med Date: 2020-02-24 Impact factor: 2.947
Authors: Minjee Kim; Eric M Liotta; Matthew B Maas; Rosemary I Braun; Blas Garcia-Canga; Daniel R Ganger; Daniela P Ladner; Kathryn J Reid; Phyllis C Zee Journal: Sleep Date: 2021-06-11 Impact factor: 5.849
Authors: Elliot B Tapper; Lilli Zhao; Samantha Nikirk; Jad Baki; Neehar D Parikh; Anna S Lok; Akbar K Waljee Journal: Am J Gastroenterol Date: 2020-12 Impact factor: 12.045
Authors: Sydni Williams; Jeremy Louissaint; Sam Nikirk; Jasmohan S Bajaj; Elliot B Tapper Journal: United European Gastroenterol J Date: 2021-02-18 Impact factor: 4.623